ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2752

Successfull Evaluation of a Predefined Set of Anatomic Sites in the Pelvis of Patients with Polymyalgia Rheumatica Showing Extracapsular Inflammation as Visualized by Contrast Enhanced Magnetic Resonance Imaging

Martin Fruth 1, Annika Seggewiss 1, Jessica Kozik 1, Philipp Martin-Seidel 1, Xenofon Baraliakos2 and Jürgen Braun 3, 1Radiology Herne, Herne, Germany, 2Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 3Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: MRI and inflammation, polymyalgia rheumatica

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T089: Imaging of Rheumatic Diseases II (2750–2755)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The diagnosis of polymyalgia rheumatica (PMR) is based on a thorough clinical evaluation of the patient – including exclusion of other diseases, since there is no decisive diagnostic test. A characteristic pattern of extracapsular inflammation in the pelvis of patients with PMR as assessed by contrast enhanced magnetic resonance imaging (MRI) has been recently described (1). We evaluated the performance of a predefined set of anatomic sites in the pelvis of patients with PMR vs. controls.

Methods: A total of 120 pelvic MRI scans of patients who had presented to our tertiary center with pelvic girdle pain in the last 3 years, including 40 patients with an expert rheumatologist diagnosis of PMR and 80 controls with other reasons of pelvic pain was evaluated by 3 radiologists blinded to clinical diagnosis and patient demographics. The experts scored the presence or absence of contrast enhancement at 19 predefined tendinous and capsular pelvic structures. Different patterns of involvement were compared and statistically evaluated by ROC analysis. Kappa statistics were applied to calculate inter- and intrareader agreement.

Results: Mostly bilateral peritendinitis and capsulitis including uncommon sites such as the proximal origins of the muscles rectus femoris and adductor longus were found almost exclusively and, thus, typically in PMR patients: the difference in the mean number of sites showing contrast enhancement was significantly different with 13.4±2.7 for PMR vs 4.0±2.3 for controls. A cut-off of ≥10 inflamed sites discriminated very well between the groups resulting in a sensitivity and specificity of 95.8% and 97.1%, respectively. Just concentrating on the most frequently involved anatomic sites bilateral inflammation of proximal M. rectus femoris or adductor longus tendons together with at least 3 other bilaterally inflamed sites performed even better with a sensitivity and specificity of 100% and 97.5%, respectively.

Conclusion: This study strongly confirms that the previously described pattern of extracapsular pelvic inflammation as assessed by contrast enhanced MRI is very typical for patients with PMR. In addition, the high sensitivity and specificity of the set of anatomic sites evaluated suggest their definite potential for use as a confirmatory diagnostic test. 

1.         Fruth M et al, Clin Exp Rheumatol. 2018


Disclosure: M. Fruth, None; A. Seggewiss, None; J. Kozik, None; P. Martin-Seidel, None; X. Baraliakos, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, BMS, 2, 5, 8, 9, Bristol-Myers Squibb, 2, 5, 8, Celgene, 2, 5, 8, 9, Chugai, 2, 5, 8, 9, Janssen, 2, 5, 8, 9, Lilly, 2, 8, 9, Merck, 2, 5, 8, MSD, 2, 5, 8, 9, Novartis, 2, 5, 8, 9, Novatis, 2, 5, 8, Pfizer, 2, 5, 8, 9, UCB, 2, 5, 8, 9, UCB Pharma, 2, 5, 8, Werfen, 2, 5, 8; J. Braun, Abbott, 2, 5, AbbVie, 2, 5, 6, 8, Amgen, 2, 5, 8, Baxter, 2, 5, 8, Biogen, 2, 8, 9, BMS, 2, 5, 8, Boehringer, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Celgene, 2, 3, 5, 8, Celltrion, 2, 5, 8, Centocor, 2, 5, 8, Chugai, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Hexal, 2, 5, 8, Janssen, 2, 5, 8, Johnson & Johnson, 2, 5, Medac, 2, 5, 8, MSD, 2, 5, MSD (Schering-Plough), 2, 5, 8, Mundipharma, 2, 5, 8, Mylan, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Pfizer (Wyeth, Hospira), 2, 5, 8, Roche, 2, 5, 8, Sanofi-Aventis, 2, 5, 8, UCB Pharma, 2, 5, 8.

To cite this abstract in AMA style:

Fruth M, Seggewiss A, Kozik J, Martin-Seidel P, Baraliakos X, Braun J. Successfull Evaluation of a Predefined Set of Anatomic Sites in the Pelvis of Patients with Polymyalgia Rheumatica Showing Extracapsular Inflammation as Visualized by Contrast Enhanced Magnetic Resonance Imaging [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/successfull-evaluation-of-a-predefined-set-of-anatomic-sites-in-the-pelvis-of-patients-with-polymyalgia-rheumatica-showing-extracapsular-inflammation-as-visualized-by-contrast-enhanced-magnetic-resona/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/successfull-evaluation-of-a-predefined-set-of-anatomic-sites-in-the-pelvis-of-patients-with-polymyalgia-rheumatica-showing-extracapsular-inflammation-as-visualized-by-contrast-enhanced-magnetic-resona/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology